June 27, 2024 06:58 AM EDT

Longevity investors look to add $200M to the table with new growth fund

Kyle LaHucik

Senior Reporter

Bold Capital Partners, a life sciences and deep tech investor, is raising a new fund to support biotechs and diagnostics makers focused on “healthy human …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Longevity investors look to add $200M to the table with new growth fund

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Longevi­ty in­vestors look to add $200M to the ta­ble with new growth fund

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Longevity investors look to add $200M to the table with new growth fund